Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 16/20 | 0.45 |
| ▸ | UBE2M | P61081 | 2/20 | 0.33 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3215282 | 0.90 | KCNH2 (0.40) | KCNH2UBE2MDCUN1D1 | |
| SCHEMBL3139141 | 0.89 | KCNH2 (0.45) | KCNH2UBE2MDCUN1D1 | |
| SCHEMBL2939431 | 0.82 | KCNH2 (0.54) | KCNH2 | |
| SCHEMBL3215289 | 0.82 | KCNH2 (0.38) | KCNH2 | |
| SCHEMBL3154490 | 0.81 | KCNH2 (0.51) | KCNH2 | |
| SCHEMBL3209294 | 0.80 | KCNH2 (0.40) | KCNH2 | |
| SCHEMBL3148962 | 0.76 | KCNH2 (0.68) | KCNH2 | |
| Hydrochloric Acid SCHEMBL3139228 | 0.76 | KCNH2 (0.67) | KCNH2 | |
| SCHEMBL5626991 | 0.76 | KCNH2 (0.55) | KCNH2 | |
| SCHEMBL3110338 | 0.75 | KCNH2 (0.42) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2136807-B1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE DERIVATIVES FOR TREATING TUBERCULOSIS | GLAXO GROUP LTD (GB) | 2010-11-03 | — | — | EP | disclosed |
| EP-1954697-B1 | PERI CONDENSED TRICYCLIC COMPOUNDS USEFUL AS ANTIBACTERIAL AGENTS | GLAXO GROUP LTD (GB) | 2010-02-24 | — | — | EP | disclosed |
| US-20080280892-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| EP-1980251-A1 | Pyrrolo[3,2,1-ij]quinoline-4-one derivatives for treating tuberculosis | GLAXO GROUP LIMITED (GB) | 2008-10-15 | — | — | EP | disclosed |
| US-20080221110-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221110-A1 | Compounds | NRDC, NISCH, MRPL21 | KCNH2 3013/4885UBE2M 375/4885DCUN1D1 2542/4885 |
| US-20080280892-A1 | Compounds | NRDC, NACA, NAA50 | KCNH2 3105/4885UBE2M 302/4885DCUN1D1 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.